葡萄籽提取物补充剂对非酒精性脂肪性肝病患者心血管风险因素、肝酶和肝脂肪变性的影响：一项随机、双盲、安慰剂对照研究。

The effects of grape seed extract supplementation on cardiovascular risk factors, liver enzymes and hepatic steatosis in patients with non-alcoholic fatty liver disease: a randomised, double-blind, placebo-controlled study.

机构信息

Student Research Committee, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.

Department of Internal Medicine, School of Medicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.

出版信息

BMC Complement Med Ther. 2024 May 16;24(1):192. doi: 10.1186/s12906-024-04477-3.

DOI:10.1186/s12906-024-04477-3

PMID:38755622

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11100156/

Abstract

BACKGROUND

Despite the high antioxidant potential of grape seed extract (GSE), very limited studies have investigated its effect on non-alcoholic fatty liver disease (NAFLD). Therefore, this study was conducted with the aim of investigating the effect of GSE on metabolic factors, blood pressure and steatosis severity in patients with NAFLD.

METHODS

In this double-blind randomized clinical trial study, 50 NAFLD patients were divided into two groups of 25 participants who were treated with 520 mg/day of GSE or the placebo group for 2 months. The parameters of glycemic, lipid profile, blood pressure and steatohepatitis were measured before and after the intervention.

RESULTS

The GSE group had an average age of 43.52 ± 8.12 years with 15 women and 10 men, while the placebo group had an average age of 44.88 ± 10.14 years with 11 women and 14 men. After 2 months of intervention with GSE, it was observed that insulin, HOMA-IR, TC, TG, LDL-c, ALT, AST, AST/ALT, SBP, DBP and MAP decreased and QUICKi and HDL-c increased significantly (p-value for all < 0.05). Also, before and after adjustment based on baseline, the average changes indicated that the levels of insulin, HOMA-IR, TC, TG, LDL-c, SBP, DBP, MAP in the GSE group decreased more than in the control group (p for all < 0.05). Furthermore, the changes in HDL-c were significantly higher in the GSE group (p < 0.05). The between-groups analysis showed a significant decrease in the HOMA-β and AST before and after adjustment based on baseline levels (p < 0.05). Moreover, the changes in QUICKi after adjustment based on baseline levels were higher in the GSE group than in the control group. Also, between-groups analysis showed that the severity of hepatic steatosis was reduced in the intervention group compared to the placebo group (P = 0.002).

CONCLUSIONS

It seems that GSE can be considered one of the appropriate strategies for controlling insulin resistance, hyperlipidemia, hypertension and hepatic steatosis in NAFLD patients.

TRIAL REGISTRATION

The clinical trial was registered in the Iranian Clinical Trial Registration Center (IRCT20190731044392N1). https://irct.behdasht.gov.ir/trial/61413 . (The registration date: 30/03/2022).

摘要

背景

尽管葡萄籽提取物（GSE）具有很高的抗氧化潜力，但很少有研究调查其对非酒精性脂肪肝（NAFLD）的影响。因此，本研究旨在调查 GSE 对 NAFLD 患者代谢因素、血压和脂肪变性严重程度的影响。

方法

在这项双盲随机临床试验研究中，将 50 名 NAFLD 患者分为两组，每组 25 名参与者，分别接受 520mg/天的 GSE 或安慰剂治疗 2 个月。干预前后测量血糖、血脂谱、血压和脂肪性肝炎参数。

结果

GSE 组平均年龄为 43.52±8.12 岁，其中女性 15 名，男性 10 名，而安慰剂组平均年龄为 44.88±10.14 岁，其中女性 11 名，男性 14 名。经过 2 个月的 GSE 干预，发现胰岛素、HOMA-IR、TC、TG、LDL-c、ALT、AST、AST/ALT、SBP、DBP 和 MAP 降低，QUICKi 和 HDL-c 升高（所有 p 值均<0.05）。此外，基于基线进行调整后，平均变化表明 GSE 组的胰岛素、HOMA-IR、TC、TG、LDL-c、SBP、DBP、MAP 水平下降幅度大于对照组（所有 p 值均<0.05）。此外，GSE 组的 HDL-c 变化显著更高（p<0.05）。基于基线的组间分析显示，HOMA-β和 AST 在调整前后均显著降低（p<0.05）。此外，基于基线进行调整后，GSE 组的 QUICKi 变化更高。此外，基于基线的组间分析显示，与安慰剂组相比，干预组的肝脂肪变性严重程度降低（P=0.002）。